The emergence of new CV-A6 recombination groups has become widespread in Europe and Asia within the last 8 years, driven by high substitution rates and recombination.
No takes yet. Share an insight, caveat, or question.
High CV-A6 substitution rate may accelerate recombinant emergence; leaves open optimal surveillance and clinical impact studies.
Puenpa et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: